Secondary outcome measures in the ITT/LOCF population
| Sham TTT baseline | Sham TTT 24 months | Difference (%) | p Value | n | TTT baseline | TTT 24 months | Difference (%) | p Value | n | |
| Area (mm2) | ||||||||||
| Mean (SD) | 2.86 (1.19) | 2.85 (1.22) | −0.30% | >0.05 | 39 | 3.31 (1.23) | 2.96 (1.40) | −10.60% | >0.05 | 45 |
| Leakage | ||||||||||
| n (%) | 9 (23.1) | 39 | 16 (34.8) | 45 | ||||||
| Fibrosis | ||||||||||
| n (%) | 20 (51.3) | 39 | 16 (34.8) | 45 | ||||||
| CRT (μm) | ||||||||||
| Mean (SD) | 378 (148) | 212 (112) | −49.9% | <0.05 | 41 | 332 (131) | 211 (116) | −36.4% | <0.05 | 47 |
Angiographic characteristics (choroidal neovascularisation lesion area, leakage and fibrosis) and central retinal thickness (CRT) in the sham transpupillary thermotherapy (TTT) and low-dose TTT-treated groups at baseline and 24 months.
ITT, intent-to-treat; LOCF, last observation carried forward.